Author

M. Stanifer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:microscopy & imaging analysis· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

S. Boulant· 4 shared B. Lucic· 2 shared C. J. Neufeldt· 2 shared M. Cortese· 2 shared M. Lusic· 2 shared R. Bartenschlager· 2 shared V. Laketa· 2 shared A. Kreshuk· 1 shared

Activity by Year

2019-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 43 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersImmunology

S. Boulant

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Increased sensitivity of SARS-CoV-2 to type III interferon in human intestinal epithelial cells

C. Kee, C. Metz-Zumaran, P. Doldan, C. Guo, M. Stanifer, S. Boulant

This study shows that type III interferons are more effective than type I interferons in reducing SARS-CoV-2 infection in human intestinal epithelial cells.

bioRxiv · Jun 14, 2021 · PreprintImmunology

The FDA-approved drug cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication

I. L. Shytaj, M. Fares, B. Lucic, L. Gallucci, M. M. Tolba, L. Zimmermann, A. T. Ayoub, M. Cortese, C. J. Neufeldt, V. Laketa, P. Chlanda, O. T. Fackler, S. Boulant, R. Bartenschlager, M. Stanifer, , M. Lusic

This study shows that cobicistat synergizes with remdesivir to inhibit SARS-CoV-2 replication in cell lines and organoids, reducing viral replication to levels comparable to uninfected cells.

bioRxiv · Mar 9, 2021Microbiology

Microscopy-based assay for semi-quantitative detection of SARS-CoV-2 specific antibodies in human sera

C. Pape, R. Remme, A. Wolny, S. Olberg, S. Wolf, L. Cerrone, M. Cortese, S. Klaus, B. Lucic, S. Ullrich, M. Anders-Össwein, S. Wolf, C. Berati, C. J. Neufeldt, M. Ganter, , V. Laketa

The paper develops a semi-quantitative microscopy-based assay to detect SARS-CoV-2 specific antibodies in human sera, providing a sensitive and specific method for serological analysis.

BioEssays · Dec 30, 2020Peer-reviewedMicrobiology

Cellular polarity asymmetrically functionalizes pathogen recognition receptor-mediated intrinsic immune response in human intestinal epithelium cells

M. Stanifer, S. Muenchau, K. Pervolaraki, T. Kanaya, M. Mukenhirn, D. Albrecht, C. Odendall, J. Kagan, S. Bartfeld, H. Ohno, S. Boulant

The paper shows that AP-1B-mediated polarized sorting of TLR3 leads to an asymmetric immune response in human intestinal epithelial cells to basolateral vs. apical infections.

bioRxiv · Nov 7, 2019 · PreprintImmunology

TRIM69 inhibits Vesicular Stomatitis Indiana Virus (VSIV)

S. J. Rihn, M. A. Aziz, D. G. Stewart, J. Hughes, M. L. Turnbull, M. Varela, E. Sugrue, C. S. Herd, M. Stanifer, S. P. Sinkins, M. Palmarini, S. J. Wilson

This study identifies TRIM69 as an interferon-induced gene that potently inhibits VSIV, with specific antiviral activity and evolutionary signatures of positive selection.

bioRxiv · Jun 13, 2019Microbiology